CEASR group | RePTA/S group | P value | |
No of patients; n | 14 | 17 | NA |
Symptomatic in-stent restenosis; n (%) | 0 (0) | 0 (0) | 1.000 |
Duration of procedure; mean±SD (min) | 86.9±23.4 | 33.5±13.4 | <0.001 |
Residual stenosis after intervention; mean±SD (%) | 0±0 | 20.9±6.7 | <0.001 |
Residual stenosis (≥30%) after intervention; n (%) | 0 (0) | 4 (23.5) | 0.040 |
Stroke/retinal infarction within 30 days after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
TIA/amaurosis fugax within 30 days after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
Myocardial infarction within 30 days after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
Death within 30 days after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
Stroke/retinal infarction within 1 year after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
TIA/amaurosis fugax within 1 year after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
Myocardial infarction within 1 year after intervention; n (%) | 0 (0) | 0 (0) | 1.000 |
Death within 1 year after intervention; n (%) | 0 (0) | 1 (5.9) | 0.548 |
Restenosis (≥70%) 1 year after intervention; n (%) | 1 (7.1) | 4 (23.5) | 0.233 |
Local complications associated with CEASR or rePTA/S within 30 days; n (%) | 2 (14.3) | 1 (5.9) | 0.704 |
Combined end-point; n (%) | 3 (21.4) | 5 (29.4) | 0.719 |
CAS, carotid artery stenting; CEASR, carotid endarterectomy with stent retrieval; n, number; NA, not available; rePTA/S, repeated percutaneous transluminal angioplasty with or without stenting; TIA, transient ischaemic attack.